BioMarin Pharmaceutical Inc. (BMRN)
Largest Insider Buys in Sector
BMRN Stock Price History Chart
BMRN Stock Performance
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Insider Activity of BioMarin Pharmaceutical Inc.
Over the last 12 months, insiders at BioMarin Pharmaceutical Inc. have bought $0 and sold $24.17M worth of BioMarin Pharmaceutical Inc. stock.
On average, over the past 5 years, insiders at BioMarin Pharmaceutical Inc. have bought $658,092 and sold $25.48M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,625 shares for transaction amount of $314,469 was made by Alles Mark J (director) on 2022‑10‑31.
List of Insider Buy and Sell Transactions, BioMarin Pharmaceutical Inc.
| 2024-11-12 | Sale | EVP, Chief Technical Officer | 5,278 0.0028% | $66.37 | $350,324 | -1.61% | ||
| 2024-08-13 | Sale | GVP, Chief Accounting Officer | 714 0.0004% | $90.00 | $64,260 | 0.00% | ||
| 2024-05-30 | Sale | EVP, Chief Financial Officer | 5,000 0.0027% | $75.19 | $375,950 | +6.19% | ||
| 2024-05-28 | Sale | EVP, Chief Legal Officer | 40,850 0.0215% | $74.51 | $3.04M | +2.66% | ||
| 2024-05-10 | Sale | director | 20,000 0.0105% | $81.14 | $1.62M | -4.92% | ||
| 2024-05-09 | Sale | director | 20,000 0.0105% | $81.62 | $1.63M | -5.68% | ||
| 2024-05-02 | Sale | EVP, Chief Commercial Officer | 5,000 0.0026% | $82.91 | $414,550 | -6.49% | ||
| 2024-05-02 | Sale | EVP, Chief Legal Officer | 1,850 0.001% | $85.01 | $157,269 | -6.49% | ||
| 2024-04-12 | Sale | director | 20,000 0.0104% | $91.26 | $1.83M | -12.46% | ||
| 2024-04-11 | Sale | director | 20,000 0.0105% | $90.99 | $1.82M | -11.70% | ||
| 2024-04-10 | Sale | GVP, Chief Accounting Officer | 2,286 0.0012% | $90.00 | $205,740 | -10.43% | ||
| 2024-03-28 | Sale | EVP, Chief Legal Officer | 24,602 0.0132% | $88.34 | $2.17M | -6.37% | ||
| 2024-03-06 | Sale | director | 1,000 0.0005% | $86.71 | $86,713 | -3.96% | ||
| 2024-03-05 | Sale | director | 1,000 0.0005% | $85.51 | $85,510 | -3.15% | ||
| 2024-03-05 | Sale | President, Worldwide R&D | 35,341 0.0186% | $85.18 | $3.01M | -3.15% | ||
| 2024-03-05 | Sale | EVP, Chief Commercial Officer | 4,000 0.0021% | $87.07 | $348,280 | -3.15% | ||
| 2024-02-27 | Sale | director | 1,000 0.0005% | $90.35 | $90,350 | -7.62% | ||
| 2024-02-09 | Sale | director | 15,000 0.0078% | $88.28 | $1.32M | -4.95% | ||
| 2024-02-08 | Sale | director | 15,000 0.0079% | $89.77 | $1.35M | -4.61% | ||
| 2024-01-10 | Sale | director | 10,000 0.0054% | $96.38 | $963,800 | -11.40% |
Insider Historical Profitability
| BIENAIME JEAN JACQUES | director | 474994 0.2492% | $66.72 | 26 | 321 | +29.88% |
| FUCHS HENRY J | President, Worldwide R&D | 212117 0.1113% | $66.72 | 0 | 72 | |
| Mueller Brian | EVP, Chief Financial Officer | 72159 0.0379% | $66.72 | 2 | 32 | +36.78% |
| Guyer Charles Greg | EVP, Chief Technical Officer | 68909 0.0362% | $66.72 | 0 | 3 | |
| Ajer Jeffrey Robert | EVP, Chief Commercial Officer | 66767 0.035% | $66.72 | 0 | 66 | |
| Davis George Eric | EVP, Chief Legal Officer | 56157 0.0295% | $66.72 | 4 | 73 | +5.04% |
| Burkhart Erin | GVP, Chief Accounting Officer | 14449 0.0076% | $66.72 | 0 | 2 | |
| WILLIAMS GWYNN | director | 812565 0.4264% | $66.72 | 0 | 8 | |
| STARR CHRISTOPHER M | SVP, Chief Scientific Officer | 295176 0.1549% | $66.72 | 0 | 7 | |
| MEIER RICHARD A | 104032 0.0546% | $66.72 | 4 | 9 | +42.46% | |
| PRICE FREDRIC D | Chief Executive Officer | 79285 0.0416% | $66.72 | 1 | 0 | <0.0001% |
| BAFFI ROBERT | EVP, Technical Operations | 71882 0.0377% | $66.72 | 8 | 30 | +11.93% |
| ASELAGE STEVE | EVP, Chief Business Officer | 59030 0.031% | $66.72 | 7 | 25 | +6.62% |
| SPIEGELMAN DANIEL K | EVP, Chief Financial Officer | 47510 0.0249% | $66.72 | 0 | 33 | |
| GREY MICHAEL G | director | 42840 0.0225% | $66.72 | 0 | 7 | |
| HERON ELAINE J | director | 41685 0.0219% | $66.72 | 0 | 7 | |
| Cooper Jeffrey H | SVP, Chief Financial Officer | 41089 0.0216% | $66.72 | 4 | 26 | <0.0001% |
| KAKKIS EMIL D | Chief Medical Officer | 39621 0.0208% | $66.72 | 6 | 14 | +3.16% |
| KLEIN JOSEPH III | director | 35000 0.0184% | $66.72 | 3 | 4 | +42.82% |
| PYOTT DAVID E I | director | 30740 0.0161% | $66.72 | 1 | 0 | +0.47% |
| LAPALME PIERRE | director | 30150 0.0158% | $66.72 | 4 | 6 | +9.26% |
| LAWLIS V BRYAN | director | 28950 0.0152% | $66.72 | 0 | 28 | |
| Slamon Dennis | director | 21639 0.0114% | $66.72 | 0 | 1 | |
| LEWIS ALAN | director | 21160 0.0111% | $66.72 | 0 | 8 | |
| Wood Mark | VP, Human Resources | 20277 0.0106% | $66.72 | 1 | 89 | +66.1% |
| Dere Willard H | director | 13290 0.007% | $66.72 | 0 | 1 | |
| Alles Mark J | director | 10905 0.0057% | $66.72 | 1 | 0 | +6.56% |
| Swiedler Stuart J | SVP, Clinical Affairs | 10000 0.0052% | $66.72 | 0 | 11 | |
| SAGER ERICH | director | 3309 0.0017% | $66.72 | 0 | 6 | |
| URQUHART JOHN | director | 0 0% | $66.72 | 0 | 1 |
Institutional Investor Ownership
| PRIMECAP Management Co | $1.63B | 9.86 | 18.71M | +1.63% | +$26.16M | 1.2 | |
| The Vanguard Group | $1.58B | 9.54 | 18.12M | +0.37% | +$5.86M | 0.03 | |
| BlackRock | $1.26B | 7.63 | 14.48M | -1.38% | -$17.72M | 0.03 | |
| Dodge & Cox | $1.22B | 7.37 | 13.99M | <0.01% | -$97,820.80 | 0.71 | |
| State Street | $602.23M | 3.63 | 6.9M | +2.45% | +$14.38M | 0.03 | |
| Capital Research Global Investors | $569.51M | 3.43 | 6.52M | -39.48% | -$371.54M | 0.13 | |
| Viking Global Investors | $560.4M | 3.38 | 6.42M | +31.23% | +$133.35M | 0.2 | |
| Ameriprise Financial | $471.95M | 2.85 | 5.4M | -0.29% | -$1.38M | 0.13 | |
| Barclays | $458.93M | 2.77 | 5.25M | -0.65% | -$3M | 0.21 | |
| UBS | $441.63M | 2.66 | 5.06M | +5,369.26% | +$433.55M | 0.13 | |
| Avoro Capital Advisors Llc | $381.24M | 2.3 | 4.37M | +1.51% | +$5.68M | 4.57 | |
| Elliott Investment Management L P | $305.72M | 1.84 | 3.5M | +16.66% | +$43.67M | 3.21 | |
| Geode Capital Management | $260.44M | 1.57 | 2.99M | +3.98% | +$9.97M | 0.02 | |
| Bank of America | $243.65M | 1.47 | 2.79M | +18.26% | +$37.63M | 0.02 | |
| BNY Mellon | $230.36M | 1.39 | 2.64M | +3.02% | +$6.75M | 0.04 | |
| JPMorgan Chase | $211.54M | 1.28 | 2.42M | -1.05% | -$2.25M | 0.02 | |
| Deutsche Bank | $204.31M | 1.23 | 2.34M | -31.24% | -$92.84M | 0.09 | |
| Millennium Management LLC | $198.89M | 1.2 | 2.28M | +94.91% | +$96.84M | 0.13 | |
| Citadel Advisors LLC | $172.55M | 1.04 | 1.98M | +456.58% | +$141.54M | 0.1 | |
| Nomura Holdings | $130.25M | 0.79 | 1.49M | -30.08% | -$56.04M | 1.14 | |
| Legal & General | $120.36M | 0.73 | 1.38M | -0.89% | -$1.08M | 0.03 | |
| Point72 Asset Management | $117.54M | 0.71 | 1.35M | +195.57% | +$77.77M | 0.17 | |
| Charles Schwab | $117.15M | 0.71 | 1.34M | -2.73% | -$3.28M | 0.03 | |
| OrbiMed | $111.66M | 0.67 | 1.28M | -18.64% | -$25.58M | 0.86 | |
| Fort Washington Investment Advisors Inc Oh | $101.95M | 0.62 | 1.17M | +0.14% | +$145,508.44 | 0.67 | |
| Manning Napier Group Llc | $100.77M | 0.61 | 1.15M | +0.76% | +$757,393.07 | 1.26 | |
| Palo Alto Investors Lp | $99.09M | 0.6 | 1.13M | -24.4% | -$31.98M | 11.18 | |
| CalPERS | $96.51M | 0.58 | 1.11M | -3.88% | -$3.9M | 0.07 | |
| T. Rowe Price | $96.28M | 0.58 | 1.1M | -31.36% | -$43.99M | 0.01 | |
| Northern Trust | $94.16M | 0.57 | 1.08M | -6.32% | -$6.35M | 0.02 | |
| Morgan Stanley | $88.24M | 0.53 | 1.01M | +7.43% | +$6.1M | 0.01 | |
| Parnassus Investments Ca | $76.25M | 0.46 | 873,001 | -52.79% | -$85.27M | 0.16 | |
| Dnb Asset Management As | $75.74M | 0.46 | 867,187 | +16.32% | +$10.63M | 0.4 | |
| Squarepoint Ops LLC | $75.22M | 0.45 | 861,217 | +209% | +$50.88M | 0.27 | |
| Nuveen | $74.62M | 0.45 | 854,392 | +39.74% | +$21.22M | 0.02 | |
| Ubs Asset Management Americas Inc | $65.05M | 0.39 | 744,801 | -0.25% | -$160,618.26 | 0.02 | |
| Dimensional Fund Advisors | $65.02M | 0.39 | 744,504 | +5.61% | +$3.45M | 0.02 | |
| HERITAGE ASSET MANAGEMENT INC | $62.06M | 0.38 | 712,529 | +63.32% | +$24.06M | 0.32 | |
| Two Sigma | $61.18M | 0.37 | 700,499 | +69.22% | +$25.03M | 0.09 | |
| Janus Henderson | $60.83M | 0.37 | 696,518 | -75.04% | -$182.88M | 0.03 | |
| Goldman Sachs | $60.55M | 0.37 | 693,224 | -23.64% | -$18.74M | 0.01 | |
| American Century Investments | $60.61M | 0.37 | 693,912 | +0.94% | +$564,915.12 | 0.04 | |
| Scout Investments | $58.87M | 0.36 | 675,868 | -14.62% | -$10.08M | 1.48 | |
| Susquehanna International Group | $59.1M | 0.36 | 676,686 | +160.71% | +$36.43M | 0.06 | |
| Fiera Capital | $53.8M | 0.32 | 615,944 | -5.94% | -$3.4M | 0.16 | |
| Swiss National Bank | $49.28M | 0.3 | 564,200 | -4.11% | -$2.11M | 0.03 | |
| Northwestern Mutual Wealth Management Co | $49.12M | 0.3 | 562,376 | +8.08% | +$3.67M | 0.05 | |
| KeyBank | $48.95M | 0.3 | 560,479 | -9.74% | -$5.28M | 0.2 | |
| Two Sigma Advisers LP | $47.6M | 0.29 | 545,014 | +62.59% | +$18.32M | 0.08 | |
| Renaissance Technologies | $47.34M | 0.29 | 542,071 | +40.19% | +$13.57M | 0.08 |